Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer

To the Editor A recent study reported on the absence of a statistically significant benefit of aspirin at 300 mg/d for recurrence and survival in patients with breast cancer. In accordance with these findings, the authors advised against the routine use of aspirin as an adjunct treatment in breast cancer.